This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	Unknown	<p>A study in mice suggests that peripheral administration of Gleevec imatinib could be useful for treating AD. In wild-type mice, intraperitoneal injection of Gleevec lowered levels of β-amyloid ($A\beta$) in the brain and plasma compared with injection of vehicle control. Next steps include testing Gleevec in AD mouse models.</p> <p>Novartis AG markets the multikinase inhibitor Gleevec to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). The study's authors have founded ModGene LLC, a company focused on discovering disease-related genes in neurological indications.</p> <p>SciBX 4(12); doi:10.1038/scibx.2011.343 Published online March 24, 2011</p>	Patented; available for licensing or partnering from ModGene	<p>Sutcliffe, J.G. <i>et al. J. Neurosci. Res.</i>; published online March 3, 2011; doi:10.1002/jnr.22603</p> <p>Contact: J. Gregor Sutcliffe, The Scripps Research Institute, La Jolla, Calif. e-mail: gregorsutcliffe@aol.com</p>